BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy
In: Molecular Therapy: Nucleic Acids, Jg. 24 (2021-06-01), S. 67-78
Online
unknown
Zugriff:
Oculopharyngeal muscular dystrophy (OPMD) is a rare autosomal dominant disease that results from an alanine expansion in the N-terminal domain of Poly-A Binding Protein Nuclear-1 (PABPN1). We have recently demonstrated that a two-vector gene therapy strategy significantly ameliorated the pathology in a mouse model of OPMD. This approach entailed intramuscular injection of two recombinant adeno-associated viruses (AAVs), one expressing three short hairpin RNAs (shRNAs) to silence both mutant and wild-type PABPN1 and one expressing a codon-optimized version of PABPN1 that is insensitive to RNA interference. Here we report the continued development of this therapeutic strategy by delivering “silence and replace” sequences in a single AAV vector named BB-301. This construct is composed of a modified AAV serotype 9 (AAV9) capsid that expresses a unique single bifunctional construct under the control of the muscle-specific Spc5-12 promoter for the co-expression of both the codon-optimized PABPN1 protein and two small inhibitory RNAs (siRNAs) against PABPN1 modeled into microRNA (miRNA) backbones. A single intramuscular injection of BB-301 results in robust inhibition of mutant PABPN1 and concomitant replacement of the codon-optimized PABPN1 protein. The treatment restores muscle strength and muscle weight to wild-type levels as well as improving other physiological hallmarks of the disease in a mouse model of OPMD.
Graphical Abstract
Alanine expansions of PABPN1 cause oculopharyngeal muscular dystrophy. Administration of a single AAV9 vector expressing a corrected version of the PABPN1 gene and two siRNAs in miRNA backbones to silence endogenous PABPN1 can restore muscle size, weight, and force in an OPMD surrogate mouse model to wild-type levels.
Titel: |
BB-301: a silence and replace AAV-based vector for the treatment of oculopharyngeal muscular dystrophy
|
---|---|
Autor/in / Beteiligte Person: | Strings-Ufombah, Vanessa ; Petrus W Roelvink ; Takahashi, Keiko ; Mukadam, Sophie ; Cappellari, Ornella ; Kao, Shih-Chu ; Trollet, Capucine ; Dickson, George ; Lu-Nguyen, Ngoc ; Harbaran, Sonal ; Suhy, David ; Malerba, Alberto ; Roth, Fanny ; Kloth, Claudia ; Kilfoil, Georgina ; Biopharma, Benitec ; Royal Holloway [University of London] (RHUL) ; Centre de recherche en Myologie – U974 SU-INSERM ; Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU) ; Gestionnaire, HAL Sorbonne Université 5 ; Centre de Recherche en Myologie |
Link: | |
Zeitschrift: | Molecular Therapy: Nucleic Acids, Jg. 24 (2021-06-01), S. 67-78 |
Veröffentlichung: | Elsevier, 2021 |
Medientyp: | unknown |
ISSN: | 2162-2531 (print) |
Schlagwort: |
|
Sonstiges: |
|